Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease.

Sage Therapeutics, Inc. announced the topline results from the Phase 2 LIGHTWAVE Study of dalzanemdor (SAGE-718) in participants with mild cognitive impairment or mild dementia due to Alzheimer's Disease. The study did not show a statistically significant difference in participants treated with dalzanemdor compared to placebo on the primary outcome measure, the WAIS-IV Coding Test score at Day 84. Despite these results, the company expressed gratitude to all involved in the research and hopes that the findings will contribute to future research in Alzheimer's Disease and related conditions. [Extracted from the article]